When the NF1 gene was discovered in 1990, it was quickly learned that the gene product functions as a regulator of a protein called Ras. Ras is a key component of a cell signaling pathway that ...

Panelists discuss how mutations in the NF1 gene lead to loss of neurofibromin function, resulting in hyperactivation of the RAS/MAPK and PI3K/AKT/mTOR pathways, and how this molecular dysregulation ...

Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American Association ...

Data suggest rigosertib stimulates an anti-cancer immune response via NLRP3 activation, providing mechanistic support for clinical trials of rigosertib-checkpoint inhibitor combinations Data reveal ...

A tissue section from a mouse model of lung metastasis showing cancer cells (green) that have attracted and activated fibroblasts (red) to support the growth of a metastatic tumor. Image: Massagué Lab ...

Chemoproteomics screening platform identified novel covalent inhibitors that specifically disrupt RAS-mediated activation of the catalytic subunit of PI 3-kinase alpha (PI3Kα) Newly identified group ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...

Researchers at Novartis BioMedical Research in the US and Switzerland have identified a molecular target that may provide a new therapeutic pathway for cancers driven by NRAS mutations. Findings ...

Phase II Study of Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and Fluorouracil in Locally Advanced Pancreatic Carcinoma: BTCRC-GI15-067 The prevalence and death rates of ...

Erasca is spending a combined $22.5 million upfront to import fresh preclinical KRAS and molecular glue assets while clearing space in its own pipeline and laying off 18% of its employees in the ...